FindTrial
Sign In

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00413751
Enrollment
20
Registered
2006-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2006-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia

Brief summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Interventions

DRUGBrimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Sponsors

Walter Reed Army Medical Center
Lead SponsorFED

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion criteria

* Patients not meeting above stated age criteria * Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study) * History of serious ocular, neurological, cardiovascular disease * History of severe systemic disease * History of arrhythmias or high blood pressure * Patients currently taking any type of ocular or systemic medications except multivitamins. * Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026